new disrupt forc mattress initi outperform
acceler approv come best-cas label scenario
pt
gross loss rate deterior balanc
color fundament focu call sedg
new ceo appoint
futur seladelpar limbo
stayin aliv -- surviv survivin peptid initi
mix model transit toward ratabl long-
analyst certif import disclosur see
new disrupt forc mattress initi outperform
launch coverag invest rate outperform price
target suggest upsid potenti roughli repres digit nativ rapidli expand omni-channel
manufactur seller patent-protect uniqu polymer-bas mattress cushion product follow period
struggl signific posit transform way compani new experienc senior leadership
fortifi core process oper market financi control recent secondari offer part
founder improv float render share worthi wall street coverag invest tradit growth-
orient money manag view today multipl share meaning underappreci firm near-
long-term sale earn power
acceler approv come best-cas label scenario pt
monday voxelotor trade name oxbryta receiv acceler approv fda three month ahead pdufa date
oxbryta repres new class disease-modifi therapi could potenti becom therapeut mainstay sickl
cell anemia sca oxbryta broad label includ adult adolesc year older sca without restrict
genotyp baselin hemoglobin view best-cas scenario base discuss kol gbt
on-going educ initi believ oxbryta wide util oxbryta annual price rang
make expens novarti recent approv adakveo aim make oxbryta avail specialti
network within two week expect substanti uptak begin reiter outperform pt
sustain growth resourc optim
critic takeaway sedg analyst day sedg doubl capac prepar growth reduc
air freight headwind storag product remain test field test come volum
uncertain sedg target run-rate end kokam busi seem realist sedg test
light-duti commerci powertrain solut view free option share sedg analyt tool layer
top manufactur autom advanc expect highli leverag remain bullish share
given potenti signific share gain commerci solar nt believ scalabl dc-dc architectur
integr offer upsid potenti dg applic grow
marvel report earn tuesday see set-up line street oct sales/ep
jan expect improv storage/dc initi ramp samsung off-set lumpi wirelin
repres one purest play work white paper could add top line next year
share content gain samsung/nok/er expect samsung ramp aggress follow nok
eric rev storag wdc/stx sale respect show sign bottom see
return prior run-rat close avera/aquantia acquisit expect sale
non-cor nxpi close qtr maintain outperform pt
gross loss rate deterior balanc sheet
given octob monthli managed/trust credit data show higher net charge-off rate yoy revisit
credit expect nco guidanc similar fairli stabl flat nco vs
possibl look forward see less increment pressur averag loss per account given larg balanc account
like slow impact new growth vertic line current on-blance-sheet averag balanc thu
number gross charged-off account would like drive total gross charge-off yoy growth full report publish today
provid extens detail vs bs credit metric give us confid today like see partner balanc
mix vs worrisom credit deterior
color fundament focu call sedg
heel givlaari earli approv present updat across rnai therapeut portfolio friday
includ increment perspect onpattro commerci expans well detail relat givlaari upcom launch
potenc toler esc platform highlight support data liver safeti signal
uln yet observ program base technolog also review disciplin approach target select
key criterion genet valid diseas context believ offer substanti de-risk recently-
appoint cfo jeff poulton discuss roi compani anticip path self-sustain reiter
new ceo appoint
bway sale y/i top our/street estim bway ship deep tm system
ocd coil recur revenu primarili gener fix leas mdd sale also includ
minor ocd revenu oper loss lower estim vs better gm/lower opex bway
ad one sale rep end rep two addit anticip bway continu target japan
reimburs approv near term upsid driver continu work toward ocd reimburs coverag
upsid potenti manag note smoking-cessation/ptsd trial track data year-end bway also
announc hire new ceo christoph von jako ph effect januari overal solid progress
futur seladelpar limbo
plan read first batch histolog slide nash trial patient complet
treatment atyp histolog find includ histolog character interfac hepat present without
biliari injuri observ abnorm frequenc interestingli enough microscop find translat
clinic symptom elev alt/ast/ggt/bilirubin seladelpar lower clinic biomark light
find termin studi nash recent initi psc studi pbc trial hold
lowest dose nash trial pbc dose sinc atyp find determin
nash dose level view pbc hold prudent
stayin aliv -- surviv survivin peptid initi outperform
initi coverag imv outperform rate cad pt tsx base potenti two indic dpx-
survivacovarian cancer dlbcl believ imv approach combin precis oncolog immunotherapi
uniqu pursu new previous undrug survivin target could lead major breakthrough oncolog
appreci opportun combin immunotherapi improv respons rate imv could potenti show
increment benefit orr ovarian/dlbcl trial success scenario could unlock increas collabor
financ larger partner acknowledg binari natur imv clinic trial consid risk-reward profil
support dcf-deriv price target valuat cad
mix model transit toward ratabl long-term outlook intact
deliv mix result surpass street revenu vs ep vs
estim yet trail product revenu vs well vs model becom
ratabl subscript servic vs outlook provid earli septemb
reiter compound-annual-growth-rate revenue/bil next-gen bill slightli up
move becom secur platform provid augment prisma cortex cloud portfolio tuck-in
acquisit aporeto machin identity-bas microsegment compani leav sour tast
lose sight lt opportun maintain outperform lower pt
report mix october-qtr result sale miss expect margins/ep strong
momentum greenlak strong annual run-rat order yoy cc demand newer product
resili compos cloud tough macro environ improv product mix along lower commod
cost help gross margin expand yoy yet transform still in-progress server exposur leav
suscept disrupt macro elong sale cycl repurchas activ slow ad risk
comfort posit thesi improv execut greenlak newer fast-grow product strong
low valuat rel peer offer compel risk/reward outlook view adjust estim given results/guid
analyt collabor infrastructur softwar
nutanix report solid sale loss-per-shar better expect posit includ encourag large-
deal momentum solid new/multi-product attach rate record sale hire also prime pump build long-term
alreadi improv pipelin backlog level manag embed macro caution hold
guidanc unchang agre right approach given lack visibl spend pattern overal come
away increment posit nutanix effect complet softwar transit make good progress
subscript transit expect sale product invest show substanti qoq increas improv
confid manag abil leverag firepow adjust estim results/guid maintain perform
increment posit bia
emerg technolog servic
report revenue/ep beat street major
segment grew q/q mix favor affect margin guidanc in-lin consensu end april
manag expect season q/q declin mid-teen consist prior year addit impact order pull-
china total impact pull-in estim cv product design activ continu strong
divers introduc robot sdk aim industri vertic first time direct collabor
merced benz commerci van also point potenti high-end cv applic enabl autom logist
near term geopolit headwind remain consequ maintain perform
intel cpu shortag may affect adopt pc
mediatek announc partnership bring modem pc anand
ericsson forecast global subscrib reach billion rcr wireless
dec cloud summit aw inventla vega nv -- next tuesday
may biotech summit featur chemistri life process institutechicago
